Floatz logo

Senaparib

Advanced Solid Tumours

Impact Therapeutics, Inc.Small moleculePhase 1/2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Advanced Solid Tumours cohort.

Asset / SponsorPhaseRating
Ceralasertib
AstraZeneca
Phase 2BB
Cyclophosphamide
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Epirubicin
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Durvalumab
AstraZeneca
Phase 1/2B

View all 50 →

Same molecule, other indications

Senaparib is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
ovarian cancerDormant
CCC
Indicative ·
53 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →